Inuvair Nexthaler

Beclometasone dipropionate and Formoterol fumarate, the active ingredients in Inuvair Nexthaler, are a combination inhaled corticosteroid and long‑acting beta2‑agonist presented as a dry‑powder inhaler for inhalation use. They treat asthma and chronic obstructive pulmonary disease in adults and adolescents.

GNH USA supplies Inuvair Nexthaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inuvair Nexthaler combines an inhaled corticosteroid and a long‑acting beta2‑agonist to manage chronic airway diseases.

Asthma: improves symptom control and reduces the frequency of exacerbations in patients with persistent asthma. COPD: enhances bronchodilation and decreases exacerbation risk in patients with chronic obstructive pulmonary disease.

Inuvair Nexthaler may cause a range of adverse reactions.

Common Side Effects: - Throat irritation or soreness - Cough or wheeze after inhalation - Hoarseness of voice - Oral candidiasis (thrush) - Headache - Tremor or shakiness

Serious or Rare Side Effects: - Paradoxical bronchospasm - Adrenal suppression with prolonged use - Pneumonia, especially in COPD patients - Cardiac arrhythmias or tachycardia - Severe hypersensitivity reactions (anaphylaxis) - Osteoporosis with long‑term high‑dose therapy

Before prescribing Inuvair Nexthaler, consider the following precautions.

Assess inhaler technique: ensure the patient can use a dry‑powder inhaler correctly. Monitor for oral candidiasis: advise rinsing the mouth after each dose. Screen for cardiovascular disease: use caution in patients with arrhythmias or ischemic heart disease. Avoid abrupt discontinuation: taper under medical supervision to prevent loss of control. Pregnancy and lactation: use only if the potential benefit justifies the potential risk. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Inuvair Nexthaler can interact with several drug classes.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator efficacy. - MAO inhibitors or tricyclic antidepressants: can increase cardiovascular side effects of formoterol. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise systemic exposure to beclometasone.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate formoterol‑induced hypokalemia. - Theophylline: additive bronchodilator effect; monitor serum levels. - Anticholinergics: may increase risk of dry mouth and throat irritation.